NCT06829121

Brief Summary

Frailty or debility is a geriatric syndrome that primarily affects older patients, but also patients with severe illnesses. It is particularly common among oncology patients, but also among patients with gastrointestinal diseases such as liver cirrhosis or pancreatitis. Sarcopenia, a component of frailty, is defined as a loss of muscle quantity, quality and function. Currently, complex methods such as CT or bioimpedance measurement are available. However, simpler techniques such as ultrasound-based measurement could be alternatives, but require further validation. The aim of this project is to be able to estimate the prognosis of patients at an early stage by measuring sarcopenia using sonography.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
900

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2020

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 20, 2022

Completed
2.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

February 4, 2025

Completed
13 days until next milestone

First Posted

Study publicly available on registry

February 17, 2025

Completed
Last Updated

February 17, 2025

Status Verified

February 1, 2025

Enrollment Period

1.6 years

First QC Date

February 4, 2025

Last Update Submit

February 10, 2025

Conditions

Keywords

muscle measurement by ultrasoundevaluation of muscle mass

Outcome Measures

Primary Outcomes (1)

  • Complication

    Number of participants with decompensation of the underlying disease (e.g. liver cirrhosis: hydropic decompensation) or death

    From date of inclusion until the date of first documented decompensation or death from any cause, whichever came first, assessed up to two years

Study Arms (1)

Ultrasound patients

Patients who receive a standard ultrasound also get a measurement of the musculature.

Diagnostic Test: Ultrasound

Interventions

UltrasoundDIAGNOSTIC_TEST

The thickness of the psoas muscle and the musculus quadriceps femoris will be measured by ultrasound

Ultrasound patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population consists of patients treated at the First Medical Clinic of the University Medical Center in Mainz who are scheduled to undergo a planned ultrasound examination.

You may qualify if:

  • All patients who receive a planned ultrasound examination as part of their outpatient or inpatient evaluation during the planned period.
  • All patients over 18 years of age.

You may not qualify if:

  • Patients under 18 years of age.
  • Patients unable to give consent.
  • Patients with neuromuscular disorders.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universitatsmedizin Mainz

Mainz, Rhineland-Palatinate, 55131, Germany

Location

Related Publications (8)

  • Hari A, Berzigotti A, Stabuc B, Caglevic N. Muscle psoas indices measured by ultrasound in cirrhosis - Preliminary evaluation of sarcopenia assessment and prediction of liver decompensation and mortality. Dig Liver Dis. 2019 Nov;51(11):1502-1507. doi: 10.1016/j.dld.2019.08.017. Epub 2019 Sep 20.

    PMID: 31547952BACKGROUND
  • Hida T, Ando K, Kobayashi K, Ito K, Tsushima M, Kobayakawa T, Morozumi M, Tanaka S, Machino M, Ota K, Kanbara S, Ito S, Ishiguro N, Hasegawa Y, Imagama S. <Editors' Choice> Ultrasound measurement of thigh muscle thickness for assessment of sarcopenia. Nagoya J Med Sci. 2018 Nov;80(4):519-527. doi: 10.18999/nagjms.80.4.519.

    PMID: 30587866BACKGROUND
  • Takai Y, Katsumata Y, Kawakami Y, Kanehisa H, Fukunaga T. Ultrasound method for estimating the cross-sectional area of the psoas major muscle. Med Sci Sports Exerc. 2011 Oct;43(10):2000-4. doi: 10.1249/MSS.0b013e31821994cb.

    PMID: 21448087BACKGROUND
  • McLean RR, Shardell MD, Alley DE, Cawthon PM, Fragala MS, Harris TB, Kenny AM, Peters KW, Ferrucci L, Guralnik JM, Kritchevsky SB, Kiel DP, Vassileva MT, Xue QL, Perera S, Studenski SA, Dam TT. Criteria for clinically relevant weakness and low lean mass and their longitudinal association with incident mobility impairment and mortality: the foundation for the National Institutes of Health (FNIH) sarcopenia project. J Gerontol A Biol Sci Med Sci. 2014 May;69(5):576-83. doi: 10.1093/gerona/glu012.

    PMID: 24737560BACKGROUND
  • Benz E, Trajanoska K, Lahousse L, Schoufour JD, Terzikhan N, De Roos E, de Jonge GB, Williams R, Franco OH, Brusselle G, Rivadeneira F. Sarcopenia in COPD: a systematic review and meta-analysis. Eur Respir Rev. 2019 Nov 13;28(154):190049. doi: 10.1183/16000617.0049-2019. Print 2019 Dec 31.

    PMID: 31722892BACKGROUND
  • Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13.

    PMID: 20392703BACKGROUND
  • Beaudart C, Zaaria M, Pasleau F, Reginster JY, Bruyere O. Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis. PLoS One. 2017 Jan 17;12(1):e0169548. doi: 10.1371/journal.pone.0169548. eCollection 2017.

    PMID: 28095426BACKGROUND
  • Xue QL. The frailty syndrome: definition and natural history. Clin Geriatr Med. 2011 Feb;27(1):1-15. doi: 10.1016/j.cger.2010.08.009.

    PMID: 21093718BACKGROUND

MeSH Terms

Conditions

SarcopeniaMuscular Atrophy

Interventions

Ultrasonography

Condition Hierarchy (Ancestors)

Neuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesAtrophyPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsSigns and Symptoms

Intervention Hierarchy (Ancestors)

Diagnostic ImagingDiagnostic Techniques and ProceduresDiagnosis

Study Officials

  • Wolfgang Maximilian Kremer WMK Kremer, MD

    Universitatsmedizin Mainz

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior physician

Study Record Dates

First Submitted

February 4, 2025

First Posted

February 17, 2025

Study Start

October 1, 2020

Primary Completion

May 20, 2022

Study Completion

December 1, 2024

Last Updated

February 17, 2025

Record last verified: 2025-02

Locations